Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

The diagnosis of primary central nervous system vasculitis.

Rice CM, Scolding NJ.

Pract Neurol. 2019 Oct 24. pii: practneurol-2018-002002. doi: 10.1136/practneurol-2018-002002. [Epub ahead of print] Review.

PMID:
31649101
2.

Author response: Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2019 Mar 19;92(12):586. doi: 10.1212/WNL.0000000000007128. No abstract available.

PMID:
30886076
3.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group.

JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.

4.

Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis.

Redondo J, Sarkar P, Kemp K, Heesom KJ, Wilkins A, Scolding NJ, Rice CM.

Stem Cells Transl Med. 2018 Oct;7(10):748-758. doi: 10.1002/sctm.18-0045. Epub 2018 Jul 31.

5.

Advising patients seeking stem cell interventions for multiple sclerosis.

von Wunster B, Bailey S, Wilkins A, Marks DI, Scolding NJ, Rice CM.

Pract Neurol. 2018 Dec;18(6):472-476. doi: 10.1136/practneurol-2018-001956. Epub 2018 May 30.

PMID:
29848512
6.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2018 May 1;90(18):819-820. doi: 10.1212/WNL.0000000000005409. Epub 2018 Mar 30. No abstract available.

PMID:
29602911
7.

Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells.

Kemp KC, Dey R, Verhagen J, Scolding NJ, Usowicz MM, Wilkins A.

Acta Neuropathol. 2018 Jun;135(6):907-921. doi: 10.1007/s00401-018-1833-z. Epub 2018 Mar 14.

8.

Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice.

Kemp KC, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook MA, Rice CM, Scolding NJ, Wilkins A.

Ann Neurol. 2018 Apr;83(4):779-793. doi: 10.1002/ana.25207.

9.

Overexpression of Kinesin Superfamily Motor Proteins in Alzheimer's Disease.

Hares K, Miners JS, Cook AJ, Rice C, Scolding N, Love S, Wilkins A.

J Alzheimers Dis. 2017;60(4):1511-1524. doi: 10.3233/JAD-170094.

PMID:
29060936
10.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

11.

Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis.

Sarkar P, Redondo J, Kemp K, Ginty M, Wilkins A, Scolding NJ, Rice CM.

Cytotherapy. 2018 Jan;20(1):21-28. doi: 10.1016/j.jcyt.2017.08.007. Epub 2017 Sep 13.

12.

Physician-assisted death should be available to people with MS - No.

Scolding N.

Mult Scler. 2017 Nov;23(13):1679-1680. doi: 10.1177/1352458517713670. Epub 2017 Sep 1. No abstract available.

PMID:
28859540
13.

Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.

Redondo J, Sarkar P, Kemp K, Virgo PF, Pawade J, Norton A, Emery DC, Guttridge MG, Marks DI, Wilkins A, Scolding NJ, Rice CM.

Mult Scler. 2018 Jun;24(7):919-931. doi: 10.1177/1352458517711276. Epub 2017 May 26.

14.

Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells.

Kemp K, Dey R, Cook A, Scolding N, Wilkins A.

Cerebellum. 2017 Aug;16(4):840-851. doi: 10.1007/s12311-017-0860-y.

15.

Cell Therapy for Multiple Sclerosis.

Sarkar P, Rice CM, Scolding NJ.

CNS Drugs. 2017 Jun;31(6):453-469. doi: 10.1007/s40263-017-0429-9. Review.

PMID:
28397112
16.

Can the optic nerve be repaired?

Wilkins A, Scolding N.

Lancet Neurol. 2017 Mar;16(3):172-173. doi: 10.1016/S1474-4422(16)30402-1. Epub 2017 Feb 15. No abstract available.

PMID:
28229881
17.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group.

Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.

PMID:
28209331
18.

Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse model.

Kemp KC, Cerminara N, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook M, Apps R, Scolding NJ, Wilkins A.

Ann Neurol. 2017 Feb;81(2):212-226. doi: 10.1002/ana.24846.

19.

Neurosarcoidosis: a clinical approach to diagnosis and management.

Ibitoye RT, Wilkins A, Scolding NJ.

J Neurol. 2017 May;264(5):1023-1028. doi: 10.1007/s00415-016-8336-4. Epub 2016 Nov 22. Review.

20.

Percutaneous Endoscopic Gastrostomy Tube Insertion in Neurodegenerative Disease: A Retrospective Study and Literature Review.

Sarkar P, Cole A, Scolding NJ, Rice CM.

Clin Endosc. 2017 May;50(3):270-278. doi: 10.5946/ce.2016.106. Epub 2016 Oct 13.

21.

Erdheim-Chester disease: 25-year history with early CNS involvement.

Rice CM, Hall CA, McCoubrie P, Renowden SA, Cohen N, Scolding NJ.

BMJ Case Rep. 2016 Oct 4;2016. pii: bcr2016216747. doi: 10.1136/bcr-2016-216747.

22.

Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP.

Blood. 2016 Dec 15;128(24):2824-2833. Epub 2016 Sep 23.

23.

Ovarioleukodystrophy due to EIF2B5 mutations.

Ibitoye RT, Renowden SA, Faulkner HJ, Scolding NJ, Rice CM.

Pract Neurol. 2016 Dec;16(6):496-499. doi: 10.1136/practneurol-2016-001382. Epub 2016 Sep 20.

PMID:
27651498
24.

Oxidative stress-related biomarkers in multiple sclerosis: a review.

Ibitoye R, Kemp K, Rice C, Hares K, Scolding N, Wilkins A.

Biomark Med. 2016 Aug;10(8):889-902. doi: 10.2217/bmm-2016-0097. Epub 2016 Jul 14. Review.

25.

Erratum to: 'Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia'.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 Jun 30;4(1):67. No abstract available.

26.

Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 May 23;4(1):53. doi: 10.1186/s40478-016-0326-3. Erratum in: Acta Neuropathol Commun. 2016;4(1):67.

27.

Oxidative injury in multiple sclerosis cerebellar grey matter.

Kemp K, Redondo J, Hares K, Rice C, Scolding N, Wilkins A.

Brain Res. 2016 Jul 1;1642:452-460. doi: 10.1016/j.brainres.2016.04.027. Epub 2016 Apr 14.

PMID:
27086975
28.

Intracranial spread of IgG4-related disease via skull base foramina.

Rice CM, Spencer T, Bunea G, Scolding NJ, Sloan P, Nath U.

Pract Neurol. 2016 Jun;16(3):240-2. doi: 10.1136/practneurol-2015-001315. Epub 2016 Feb 8.

PMID:
26856357
29.

Axonal motor protein KIF5A and associated cargo deficits in multiple sclerosis lesional and normal-appearing white matter.

Hares K, Redondo J, Kemp K, Rice C, Scolding N, Wilkins A.

Neuropathol Appl Neurobiol. 2017 Apr;43(3):227-241. doi: 10.1111/nan.12305. Epub 2016 Apr 1.

PMID:
26785938
30.

Tumefactive demyelination presenting during bevacizumab treatment.

Rice CM, Rossiter D, Fehmi J, Stevens JC, Renowden SA, Cohen N, Bailey C, Scolding NJ.

BMJ Case Rep. 2015 Dec 16;2015. pii: bcr2015212173. doi: 10.1136/bcr-2015-212173.

31.

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP.

Mult Scler. 2016 Aug;22(9):1215-23. doi: 10.1177/1352458515614092. Epub 2015 Oct 29.

PMID:
26514979
32.

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.

Rice CM, Marks DI, Ben-Shlomo Y, Evangelou N, Morgan PS, Metcalfe C, Walsh P, Kane NM, Guttridge MG, Miflin G, Blackmore S, Sarkar P, Redondo J, Owen D, Cottrell DA, Wilkins A, Scolding NJ.

Trials. 2015 Oct 14;16:463. doi: 10.1186/s13063-015-0953-1.

33.

Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).

Rice CM, Marks DI, Walsh P, Kane NM, Guttridge MG, Redondo J, Sarkar P, Owen D, Wilkins A, Scolding NJ.

BMJ Open. 2015 Sep 11;5(9):e009090. doi: 10.1136/bmjopen-2015-009090.

34.

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.

Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A, Giovannoni G, Miller D, Rashid W, Schmierer K, Shehu A, Silber E, Young C, Zajicek J.

Pract Neurol. 2015 Aug;15(4):273-9. doi: 10.1136/practneurol-2015-001139. Epub 2015 Jun 22. No abstract available.

PMID:
26101071
35.

The best clinical paper on multiple sclerosis in 2014.

Scolding N.

Mult Scler. 2015 Jun;21(7):854-5. doi: 10.1177/1352458515584416. Epub 2015 May 7. No abstract available.

PMID:
25953012
36.

Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.

Rice CM, Kurian KM, Renowden S, Whiteway A, Price C, Scolding NJ.

J Neurol. 2015 May;262(5):1354-9. doi: 10.1007/s00415-015-7720-9. Epub 2015 Apr 7.

PMID:
25843450
37.

Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.

Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC.

Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(3):e93. doi: 10.1212/NXI.0000000000000093. eCollection 2015 Jun.

38.

Reductions in kinesin expression are associated with nitric oxide-induced axonal damage.

Redondo J, Hares K, Wilkins A, Scolding N, Kemp K.

J Neurosci Res. 2015 Jun;93(6):882-92. doi: 10.1002/jnr.23556. Epub 2015 Jan 29.

39.

Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum.

Redondo J, Kemp K, Hares K, Rice C, Scolding N, Wilkins A.

Brain Pathol. 2015 Nov;25(6):692-700. doi: 10.1111/bpa.12230. Epub 2014 Dec 31.

40.

Cell fusion in the brain: two cells forward, one cell back.

Kemp K, Wilkins A, Scolding N.

Acta Neuropathol. 2014 Nov;128(5):629-38. doi: 10.1007/s00401-014-1303-1. Epub 2014 Jun 5. Review.

41.

Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.

Robertson NP, Scolding NJ.

Neurology. 2014 Jun 17;82(24):2150-1. doi: 10.1212/WNL.0000000000000530. Epub 2014 May 16. No abstract available.

PMID:
24838787
42.

Increased microglial catalase activity in multiple sclerosis grey matter.

Gray E, Kemp K, Hares K, Redondo J, Rice C, Scolding N, Wilkins A.

Brain Res. 2014 Apr 22;1559:55-64. doi: 10.1016/j.brainres.2014.02.042. Epub 2014 Mar 3.

PMID:
24602691
43.

Acute disseminated encephalomyelitis and other inflammatory demyelinating variants.

Scolding N.

Handb Clin Neurol. 2014;122:601-11. doi: 10.1016/B978-0-444-52001-2.00026-1. Review.

PMID:
24507537
44.

Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.

Hares K, Kemp K, Rice C, Gray E, Scolding N, Wilkins A.

Mult Scler. 2014 Jun;20(7):812-21. doi: 10.1177/1352458513508836. Epub 2013 Oct 21.

PMID:
24144874
45.

Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.

Rice CM, Kemp K, Wilkins A, Scolding NJ.

Lancet. 2013 Oct 5;382(9899):1204-13. doi: 10.1016/S0140-6736(13)61810-3.

PMID:
24095194
46.

Reductions in neuronal peroxisomes in multiple sclerosis grey matter.

Gray E, Rice C, Hares K, Redondo J, Kemp K, Williams M, Brown A, Scolding N, Wilkins A.

Mult Scler. 2014 May;20(6):651-9. doi: 10.1177/1352458513505691. Epub 2013 Sep 25.

PMID:
24067896
47.

How I start a new patient consultation.

Allen C, Scolding N, Mumford C, Smith P, Fuller G.

Pract Neurol. 2013 Aug;13(4):254-7. doi: 10.1136/practneurol-2013-000564. Epub 2013 Apr 10. No abstract available.

PMID:
23576765
48.

Primary progressive multiple sclerosis: progress and challenges.

Rice CM, Cottrell D, Wilkins A, Scolding NJ.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1100-6. doi: 10.1136/jnnp-2012-304140. Epub 2013 Feb 16. Review.

PMID:
23418213
49.

Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum.

Kemp K, Gray E, Wilkins A, Scolding N.

Brain. 2012 Oct;135(Pt 10):2962-72. doi: 10.1093/brain/aws226. Epub 2012 Sep 13.

PMID:
22975392
50.

Human mesenchymal stem cells increase anti-oxidant defences in cells derived from patients with Friedreich's ataxia.

Dey R, Kemp K, Gray E, Rice C, Scolding N, Wilkins A.

Cerebellum. 2012 Dec;11(4):861-71. doi: 10.1007/s12311-012-0406-2.

PMID:
22826109

Supplemental Content

Loading ...
Support Center